Michela Maur

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín et al. · Journal for ImmunoTherapy of Cancer · 2022 · 156 citations · Full text

Medicine, Oncology, Pharmacology +17

Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma

Michela Maur, Chiara Tomasello, Antonio Frassoldati et al. · Journal of Clinical Oncology · 2011 · 127 citations · Full text

Medicine, Neurology, Oncology +13

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

Neeraj Agarwal, Jean-Pascal Machiels, Cristina Suárez et al. · The Oncologist · 2016 · 81 citations · Full text

Medicine, Oncology, Pharmacology +15

Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study

Enriqueta Felip, Filippo de Braud, Michela Maur et al. · Journal of Thoracic Oncology · 2019 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang et al. · Journal of Experimental & Clinical Cancer Research · 2022 · 77 citations · Full text

Medicine, Oncology, Pharmacology +16